- LEMS is a rare autoimmune disorder characterized by muscle weakness of the limbs, often associated with underlying malignancies such as small-cell lung cancer. The condition is treated using symptomatic therapies like potassium channel blockers and immunomodulatory treatments such as corticosteroids and IVIG
- The market is growing due to advancements in targeted drug development, improved patient registries, and expanded access to immunotherapy in rare disease centers
- North America holds the largest market share due to faster diagnosis, high availability of orphan drugs, and advanced healthcare systems
- Asia-Pacific is witnessing rising diagnostic rates, with governments initiating rare disease coverage policies and funding registries to improve disease tracking and patient access
- The potassium channel blockers segment is projected to dominate the market with the largest share of 48.1%, due to their primary role in managing neuromuscular transmission symptoms and regulatory recognition as the standard of care in LEMS
